Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double Blind, Active-controlled, Phase Ⅲ Study to Evaluate the Immunogenicity and Safety of 'Ilyang Flu Vaccine Pre-filled Syringe Inj.(Influenza Split Vaccine)' in Healthy Children Aged From 6 Months to < 18 Years.

NCT02263131 is registered in ClinicalTrials.gov with Il-Yang Pharm. Co., Ltd. as lead sponsor.

NCT NCT02263131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02263131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double Blind, Active-controlled, Phase Ⅲ Study to Evaluate the Immunogenicity and Safety of 'Ilyang Flu Vaccine Pre-filled Syringe Inj.(Influenza Split Vaccine)' in Healthy Children Aged From 6 Months to < 18 Years.
Lead sponsor
Il-Yang Pharm. Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2013
Completion date
June 30, 2014
Enrollment
416 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy